Találati lista | Tudóstér

001-es BibID:	BIBFORM126272
035-os BibID:	(scopus)85204235831 (wos)001309611300001
Első szerző:	Siriratnam, Pakeeran
Cím:	Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD : multicentre study / Siriratnam P., Sanfilippo P., van der Walt A., Sharmin S., Foong Y. C., Yeh W. Z., Zhu C., Khoury S. J., Csepany T., Willekens B., Etemadifar M., Ozakbas S., Nytrova P., Altintas A., Al-Asmi A., Yamout B., Laureys G., Patti F., Simo M., Surcinelli A., Foschi M., McCombe P. A., Alroughani R., Sánchez-Menoyo J. L., Turkoglu R., Soysal A., Lechner Scott J., Kalincik T., Butzkueven H., Jokubaitis V., Huda S., Monif M. MSBASE study group
Dátum:	2024
ISSN:	0022-3050 1468-330X
Megjegyzések:	Background: Neuromyelitis optica spectrum disorder (NMOSD) can be categorised into aquaporin-4 antibody (AQP4-IgG) NMOSD or seronegative NMOSD. While our knowledge of AQP4-IgG NMOSD has evolved significantly in the past decade, seronegative NMOSD remains less understood. This study aimed to evaluate the predictors of relapses and treatment responses in AQP4-IgG NMOSD and seronegative NMOSD. Methods: This was a multicentre, international, retrospective cohort study using the MSBase registry. Recurrent relapse risk was assessed using an Andersen-Gill model and risk of first relapse was evaluated using a Cox proportional hazards model. Covariates that putatively influence relapse risk included demographic factors, clinical characteristics and immunosuppressive therapies; the latter was assessed as a time-varying covariate. Results: A total of 398 patients (246 AQP4-IgG NMOSD and 152 seronegative NMOSD) were included. The AQP4-IgG NMOSD and seronegative NMOSD patients did not significantly differ by age at disease onset, ethnicity or annualised relapse rate. Both low-efficacy and high-efficacy immunosuppressive therapies were associated with significant reductions in recurrent relapse risk, with notably greater protection conferred by high-efficacy therapies in both AQP4-IgG NMOSD (HR 0.27, 95% CI 0.15 to 0.49, p<0.001) and seronegative NMOSD (HR 0.21, 95% CI 0.08 to 0.51, p<0.001). Longer disease duration (HR 0.97, 95% CI 0.95 to 0.99, p<0.001) and male sex (HR 0.52, 95% CI 0.34 to 0.84, p=0.007) were additional protective variables in reducing the recurrent relapse risk for the AQP4-IgG NMOSD group. Conclusion: Although further studies are needed to improve our understanding of seronegative NMOSD, our findings underscore the importance of aggressive treatment with high-efficacy immunotherapies in both NMOSD subtypes, regardless of serostatus.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban folyóiratcikk HEALTH ECONOMICS IMMUNOLOGY MEDICINE MULTIPLE SCLEROSIS NEUROIMMUNOLOGY
Megjelenés:	Journal of Neurology, Neurosurgery, and Psychiatry. - [Epub ahead of print] (2024). -
További szerzők:	Sanfilippo, Paul Walt, Anneke van der Sharmin, Sifat Foong, Yi Chao Yeh, Wei Zhen Zhu, Chao Khoury, Samia J. Csépány Tünde (1956-) (neurológus, pszichiáter) Willekens, Barbara Etemadifar, Masoud Ozakbas, Serkan Nytrova, Petra Altintas, Ayse Al-Asmi, Abdullah Yamout, Bassem Laureys, Guy Patti, Francesco Simó Magdolna Surcinelli, Andrea Foschi, Matteo McCombe, Pamela Alroughani, Raed Sanchez-Menoyo, Jose Turkoglu, Recai Soysal, Aysun Lechner Scott, Jeanette Kalincik, Tomas Butzkueven, Helmut Jokubaitis, Vilija Huda, Saif Monif, Mastura MSBase Study Group
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: